PhaseBio Pharmaceuticals Net Income

PhaseBio Pharmaceuticals posts a net income of $28M as of June 2022. That compares with $-110M in the prior-year period — up 125.0% year over year. That is below the Healthcare sector average of $17B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, PhaseBio Pharmaceuticals's net income was $-110M. The latest reading is $28M — a 125.0% year-over-year increase (period ending June 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a net income near $17B is typical. PhaseBio Pharmaceuticals's $28M is lower that level. That is roughly 99.8% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of PhaseBio Pharmaceuticals's financial statement story. At $28M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PHAS's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $17B), and (3) consistency with growth and profitability. This page covers the first two; PhaseBio Pharmaceuticals's other metric pages and overview cover the third.